List of Excipients in Branded Drug JUXTAPID

JUXTAPID Excipient Strategy and Commercial Opportunities: Lomitapide Formulation, Generic Entry, and Patent Risk

Last updated: September 5, 2026

Juxtapid is an oral lomitapide capsule approved for adults with homozygous familial hypercholesterolemia, or HoFH. Its commercial value is driven less by excipient complexity than by orphan-disease pricing, severe safety restrictions, limited patient numbers, and regulatory barriers associated with hepatic toxicity and CYP3A4 interactions. The strongest excipient opportunities are controlled-release alternatives, pediatric or swallowing-friendly presentations, manufacturing-cost reductions, and differentiated formulations that can support a 505(b)(2) strategy.

What is Juxtapid and how is lomitapide formulated?

Juxtapid contains lomitapide, a microsomal triglyceride transfer protein inhibitor. It is marketed in hard-gelatin capsules at 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, and 60 mg strengths under FDA NDA 203858. The product is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments for adults with HoFH [1].

Juxtapid is administered once daily without food, at least two hours after the evening meal. The label limits the maximum dose to 60 mg daily and requires liver-function monitoring. The drug is subject to an FDA Risk Evaluation and Mitigation Strategy, or REMS, because of the risk of hepatotoxicity [1].

Juxtapid dosage-form profile

Attribute	Juxtapid profile
Active ingredient	Lomitapide
Therapeutic class	Microsomal triglyceride transfer protein inhibitor
FDA application	NDA 203858
Dosage form	Immediate-release oral capsule
Strengths	5, 10, 20, 30, 40, 60 mg
Administration	Once daily without food
Target population	Adults with homozygous familial hypercholesterolemia
Key safety issue	Hepatotoxicity and hepatic steatosis
Regulatory controls	REMS, liver monitoring, contraindications and CYP3A4 restrictions
Original sponsor	Aegerion Pharmaceuticals
Current commercial owner	Amryt Pharma, acquired by Chiesi Farmaceutici

The capsule excipient system is conventional for an immediate-release solid oral product. FDA labeling identifies inactive ingredients including lactose monohydrate, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, talc, and capsule-shell components such as gelatin and titanium dioxide. Colorants vary by capsule strength [1].

What excipients are used in Juxtapid capsules?

The principal excipients perform standard functions:

Excipient category	Juxtapid role	Commercial relevance
Lactose monohydrate	Diluent and bulking agent	Potential issue for lactose-sensitive patients and supply-chain substitution
Microcrystalline cellulose	Filler and compressibility aid	Supports capsule-fill uniformity
Pregelatinized starch	Binder and disintegrant	Helps achieve immediate release
Croscarmellose sodium	Superdisintegrant	Supports capsule-content dispersion
Colloidal silicon dioxide	Glidant	Improves powder flow
Magnesium stearate	Lubricant	Controls manufacturing friction
Talc	Processing aid and anti-adherent	May be subject to customer or regional preferences
Gelatin	Capsule shell	Creates vegetarian, religious, and supply-chain substitution considerations
Titanium dioxide and iron oxides	Capsule-shell colorants	May require alternative-color strategies in some markets

The formulation is not dependent on a sophisticated delivery platform. Its technical challenge is the drug substance and clinical-use profile rather than an unusually complex excipient matrix. Lomitapide is highly lipophilic, and food substantially affects exposure. The approved product therefore uses a strict fasting-related administration instruction instead of a lipid-based formulation designed to exploit fed-state absorption [1].

What excipient opportunities exist for Juxtapid?

The strongest opportunities involve patient usability, exposure control, and lifecycle management rather than simple excipient substitution.

1. Pediatric and swallowing-friendly formulations

HoFH is a genetic disorder that can affect children and adolescents. Juxtapid’s U.S. labeling is for adults, creating a potential development opportunity for:

• Oral granules or sprinkle capsules
• Powder-for-reconstitution products
• Mini-tablets
• Low-dose multiparticulates
• Palatable oral suspensions
• Non-gelatin capsules
• Smaller capsule presentations

Any pediatric formulation would require clinical bridging, dose-exposure assessment, palatability work, and an appropriate regulatory pathway. A pediatric presentation could also reduce the practical burden created by six commercial strengths.

2. Dose-flexible multiparticulate systems

A multiparticulate formulation could allow several dose levels using a single platform. Possible approaches include:

• Coated drug-loaded pellets
• Capsule-in-capsule systems
• Sprinkle granules
• Extemporaneous suspension-compatible particles
• Unit-dose sachets

The value proposition is operational. A single manufacturing platform could support 5 mg through 60 mg dosing with fewer finished-product configurations. The approach would need to preserve the product’s immediate-release behavior and fasting administration requirements.

3. Alternative capsule shells

A non-gelatin shell could address:

• Vegetarian and vegan market requirements
• Religious certification
• Gelatin supply constraints
• Regional excipient preferences

Hydroxypropyl methylcellulose, or HPMC, is the most obvious alternative shell material. A shell change would require comparative dissolution, moisture-permeation, stability, and bioequivalence analysis. Shell substitution alone is unlikely to create strong patent protection unless combined with a novel stability or delivery result.

4. Excipient substitution and supply-chain resilience

The existing formulation relies on widely available excipients. A generic or authorized-generic sponsor could evaluate:

• Lactose-free diluent systems
• Starch-free formulations
• Alternative glidants
• Magnesium-stearate replacement
• Lower-moisture capsule shells
• Iron-oxide or titanium-dioxide alternatives

The commercial benefit would be lower cost, dual sourcing, and access to customers with excipient restrictions. These changes are more likely to support manufacturing differentiation than market exclusivity.

5. Modified-release or exposure-moderating products

Lomitapide’s safety profile creates a potential rationale for exposure moderation. A sustained-release or delayed-release product could seek to reduce peak concentrations, improve tolerability, or alter hepatic exposure. The development risk is substantial because the product’s pharmacology, food effect, and liver-safety relationship would require new clinical evidence.

A modified-release product could qualify for 505(b)(2) treatment if it relies partly on FDA’s findings for the reference product while requiring new investigations. The opportunity is technically attractive but commercially dependent on proving a meaningful safety, adherence, or dosing advantage.

What patents protect Juxtapid and its formulation?

Juxtapid protection has historically involved several patent layers:

1. Lomitapide composition-of-matter protection.
2. Pharmaceutical composition patents.
3. Method-of-use claims for HoFH and lipid reduction.
4. Formulation and dosage-regimen claims.
5. Regulatory exclusivity associated with the orphan indication.

Public patent databases identify U.S. lomitapide patent families including U.S. Patent No. 7,932,268 and later patents directed to lomitapide compositions, treatment methods, and related formulations. Patent scope and expiration dates vary by family, terminal disclaimers, patent-term adjustment, and pediatric exclusivity. The FDA Orange Book entry and USPTO records are the controlling sources for current U.S. listed-patent status [2, 3].

How strong is the Juxtapid patent estate?

The patent estate is stronger against a basic same-formulation competitor when composition-of-matter or broad pharmaceutical-composition claims remain enforceable. It is weaker against a technically distinct product that:

• Uses a different excipient system;
• Employs a different capsule shell;
• Uses a separate release profile;
• Pursues a 505(b)(2) application;
• Challenges method-of-use claims through a Paragraph IV certification.

Excipient changes generally do not avoid a composition-of-matter patent covering lomitapide itself. They can, however, reduce exposure to narrower formulation claims.

When did Juxtapid lose orphan exclusivity?

FDA approved Juxtapid in December 2012. The product received seven years of U.S. orphan-drug exclusivity, which generally ran through December 2019 for the approved HoFH indication [1, 4].

Orphan exclusivity blocked FDA approval of the same drug for the same disease or condition during the exclusivity period, subject to statutory exceptions. It did not prevent all forms of patent litigation, off-label competition, or development of a product that did not meet the same-drug and same-indication criteria.

The end of orphan exclusivity opened the principal regulatory pathway for generic or 505(b)(2) competition, but commercial entry still depends on listed patents, bioequivalence, REMS requirements, manufacturing capability, and market economics.

What is the Orange Book status of Juxtapid?

The Orange Book identifies FDA-approved products and listed patents for approved drug applications. Juxtapid’s relevant entry is associated with NDA 203858. A potential abbreviated new drug application, or ANDA, sponsor must evaluate:

• Drug substance and drug-product patents listed for the reference product;
• Paragraph I, II, III, or IV certification options;
• Pediatric exclusivity;
• Any patent-listing disputes;
• REMS obligations;
• Required bioequivalence studies;
• Labeling differences caused by patent-protected indications.

A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. If the innovator files suit within the statutory period, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and litigation developments [5].

Which companies are challenging or competing with Juxtapid?

The competitive environment has two levels.

Direct lomitapide competition

Potential direct competitors include:

• Generic lomitapide capsule manufacturers;
• Authorized-generic suppliers;
• 505(b)(2) developers pursuing alternative dosage forms;
• Regional manufacturers in markets without equivalent patent barriers.

The small HoFH population limits the number of economically attractive entrants. A generic sponsor must support pharmacokinetic studies, formulation development, pharmacovigilance, and potentially a REMS-compatible distribution model.

Therapeutic competitors

Juxtapid competes clinically with:

• Evinacumab, marketed as Evkeeza;
• PCSK9 inhibitors such as evolocumab and alirocumab;
• Inclisiran;
• LDL apheresis;
• High-intensity statins and ezetimibe as background treatment;
• Other specialized lipid-lowering approaches.

Evinacumab is particularly relevant because it is also approved for HoFH and uses a monoclonal-antibody pathway. It does not create a conventional small-molecule generic opportunity, but it increases pressure on Juxtapid’s adherence, tolerability, and reimbursement position [6].

What generic entry risks exist for Juxtapid?

The main generic-entry scenarios are:

Scenario	Product	Likely commercial effect
Single generic entrant	Same-strength immediate-release capsules	Moderate price erosion, limited volume expansion
Multiple ANDA entrants	Several capsule suppliers	Greater price compression and contracting pressure
Authorized generic	Innovator-linked generic	Preserves some revenue while controlling erosion
505(b)(2) product	New shell, release profile, or pediatric form	Potential premium pricing if clinically differentiated
Regional generic entry	Non-U.S. or less restrictive market	Variable impact on U.S. revenue
Therapeutic substitution	Evinacumab or other lipid therapies	Erodes demand without direct patent infringement

Because HoFH is rare, the market may not support many manufacturers. A first entrant could capture meaningful share even if total volume remains low. The primary commercial risk is price reduction rather than a large increase in unit demand.

How can excipients support commercial differentiation?

An excipient strategy should be linked to a specific market or regulatory objective.

Objective	Formulation strategy	Commercial rationale
Lower manufacturing cost	Replace or optimize diluent, glidant, and lubricant system	Improves gross margin
Pediatric use	Sprinkle capsule, granule, or suspension	Expands age range and adherence
Vegetarian positioning	HPMC capsule shell	Broadens patient and market acceptance
Dose flexibility	Multiparticulate platform	Reduces SKU complexity
Improved stability	Moisture-barrier shell or packaging	Extends shelf life and reduces waste
Improved tolerability	Modified-release formulation	Creates a potential 505(b)(2) distinction
Regional access	Local excipient sourcing	Reduces import and supply risk
Patient convenience	Smaller capsule or alternative presentation	Supports adherence and differentiation

An excipient-only reformulation is unlikely to support premium pricing unless it solves a documented patient or manufacturing problem. The most defensible opportunity is a formulation that combines excipient innovation with new clinical utility, such as pediatric dosing, lower pill burden, improved tolerability, or easier administration.

What licensing and partnering opportunities exist?

Potential licensing targets include:

• Rights to an authorized generic;
• Regional commercialization licenses;
• Pediatric formulation technology;
• HPMC capsule platforms;
• Multiparticulate manufacturing technologies;
• 505(b)(2) development partnerships;
• Co-development with specialty-pharma companies serving rare lipid disorders.

Amryt Pharma acquired Aegerion, and Chiesi Farmaceutici later acquired Amryt. These ownership changes make direct licensing of Juxtapid-related rights dependent on the current Chiesi portfolio and transaction strategy [7]. A generic manufacturer is more likely to pursue an independent ANDA or supply agreement than a broad formulation license unless it requires access to manufacturing know-how, regulatory documentation, or an authorized-generic arrangement.

What manufacturing and regulatory barriers affect Juxtapid?

The principal barriers are:

• Control of lomitapide drug-substance quality;
• Consistent low-dose capsule filling;
• Content uniformity across multiple strengths;
• Stability under moisture and temperature stress;
• Bioequivalence under fasting conditions;
• REMS-compatible distribution;
• Liver-safety labeling and pharmacovigilance;
• Limited patient recruitment for comparative studies;
• Specialty-pharmacy and reimbursement management.

A manufacturer pursuing a generic product must also address the reference product’s restricted-use context. The FDA’s REMS requirements can affect sponsor obligations, although FDA may determine that a shared system is unnecessary or impractical in a particular case [1, 5].

How does Juxtapid compare with Evkeeza?

Attribute	Juxtapid	Evkeeza
Active ingredient	Lomitapide	Evinacumab
Modality	Small molecule	Monoclonal antibody
Administration	Oral capsule	Intravenous infusion
FDA indication	HoFH	HoFH
Generic pathway	ANDA possible after relevant exclusivities and patents	Biosimilar pathway
Main safety concern	Hepatotoxicity, hepatic fat accumulation	Infusion reactions and other biologic-related risks
Excipient opportunity	Capsule, granule, suspension, release modification	Infusion formulation and biologic stability
Manufacturing barrier	Small-molecule API and capsule quality	Cell-line, purification, sterile fill-finish
Commercial differentiation	Oral convenience and formulation flexibility	Non-MTP mechanism and clinical positioning

Juxtapid has a simpler dosage form but a more restrictive hepatic-safety profile. Evkeeza has greater manufacturing complexity and no conventional small-molecule generic pathway, but its biologic status may support longer-term market protection.

Key Takeaways

• Juxtapid is an immediate-release lomitapide capsule for adults with HoFH.
• Its excipient system is conventional and does not, by itself, create a strong barrier to generic development.
• The highest-value excipient opportunities involve pediatric formulations, multiparticulates, non-gelatin shells, stability improvements, and potentially modified release.
• U.S. orphan exclusivity began with the December 2012 approval and generally ended in December 2019.
• Patent risk depends on composition-of-matter, formulation, method-of-use, and dosage-regimen claims listed for NDA 203858.
• A Paragraph IV challenge remains the principal U.S. litigation route for an ANDA sponsor facing unexpired listed patents.
• The market is commercially attractive because of rare-disease pricing but constrained by the small HoFH population, REMS obligations, hepatic monitoring, and competing therapies.
• The strongest lifecycle strategy is a clinically differentiated formulation, not a cosmetic excipient substitution.
• Chiesi’s ownership of the Amryt portfolio is relevant to licensing, authorized-generic, and regional commercialization opportunities.

FAQs on Juxtapid excipient and patent opportunities

Can lactose-free lomitapide capsules create a new market opportunity?

Yes, but the opportunity is primarily patient-access and supply-chain differentiation. A lactose-free formulation would not avoid a patent covering lomitapide itself and would require pharmaceutical equivalence or an appropriate 505(b)(2) strategy.

Can Juxtapid be reformulated as an oral suspension?

Potentially. An oral suspension could address pediatric and swallowing difficulties, but it would require development of dose uniformity, physical stability, microbial control, palatability, and bioequivalence or clinical bridging data.

Is an HPMC capsule commercially preferable to a gelatin capsule?

An HPMC capsule can expand access for vegetarian, vegan, religious, and regional markets. The commercial benefit depends on demonstrated stability and customer demand because shell substitution alone usually does not justify a substantial price premium.

Could a sustained-release lomitapide product reduce liver toxicity?

It could be investigated, but reduced peak exposure would not establish reduced liver toxicity. A modified-release product would require clinical evidence linking the new pharmacokinetic profile to a meaningful safety or adherence benefit.

Does Juxtapid have biosimilar competition?

No. Lomitapide is a small molecule, so competing products would generally use the ANDA generic pathway or, for a materially changed product, the 505(b)(2) pathway. Biosimilar competition applies to biologic HoFH therapies such as evinacumab, not to Juxtapid.

References

1. U.S. Food and Drug Administration. (2023). Juxtapid (lomitapide) capsules: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. United States Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for lomitapide patent families.
4. U.S. Food and Drug Administration. (2012). FDA approves Juxtapid to treat homozygous familial hypercholesterolemia.
5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Patent certifications and exclusivity provisions.
6. U.S. Food and Drug Administration. (2021). Evkeeza (evinacumab-dgnb) injection: Prescribing information.
7. Chiesi Farmaceutici S.p.A. (2023). Chiesi Farmaceutici completes acquisition of Amryt Pharma.